ClinicalTrials.gg
RecruitingNCT06817954Updated May 1, 2026

To Evaluate the Effectiveness and Safety of Mastectomy Combined With Immediate Breast Reconstruction in Breast Cancer (NJMU-Reconstruction Cohort)

An interventional study of endoscopic-assisted mastectomy and immediate breast reconstruction and mastectomy and immediate breast reconstruction in Breast Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
800
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University — 39 open to participants now, 40 under way, none of them phase 3. Breast Neoplasms · The First Affiliated Hospital with Nanjing Medical University.

Planned enrollment
5th of 44
800 · median 76
Started
2025
with 5 others
No phase
15 of 57
12 open now
Primary completion
2027-12
later than 29 of 39 live
Registered
37th of 57
by date

Among the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University, this one is the 5th largest by planned enrollment of the 44 interventional ones that give a count, is one of 6 that started in 2025, is one of 15 with no phase, reaches primary completion later than 29 of the 39 other live ones, and was the 37th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

39 of the 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University are open now, in 1 country. Recruiting first, the newest first:

33 more — sign in →

By country, each count listing its studies:

All 39 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies in Breast Neoplasms by The First Affiliated Hospital with Nanjing Medical University, or all of them as a file.
02

Study summary

The new technology of endoscopic-assisted system, as an emerging technology, has shown certain application prospects in breast surgery. However, the new technology of endoscopic-assisted mastectomy and immediate breast reconstruction in China in the treatment of breast cancer is still in the exploratory stage and needs to be further improved. This prospective, single-center, double-arm clinical study was conducted to use the endoscopic-assisted system and evaluate the effectiveness and safety of the mastectomy combined with immediate breast reconstruction in breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Endoscopic-assisted mastectomy and immediate breast reconstruction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female patients, aged 18-75 years old; The pregnancy test (-) and reliable methods are required for premenopausal and perimenopausal patients;
  2. Patients with the diagnosed breast cancer confirmed by core needle and unilateral operation was performed; Breast cancer patients with tumor node stage 0-III according to the 8th edition of the American Joint Commission on Cancer; Preoperative clinical examination or imaging evaluation shows that the distance between the tumor and the Nipple Areolar Complex (NAC) is more than 1cm. The tumor has a diameter of 2-3 cm and can be located in any quadrant or reduced to 3 cm through preoperative chemotherapy. The distance between the lesion and the skin should be at least 8-10 mm;
  3. There is no clinical or imaging evidence to prove that the tumor has invaded the skin, chest wall, or nipple areola complex;
  4. There are indications for breast preservation, but the patient has a strong desire for reconstruction and is unwilling to undergo breast preservation surgery;
  5. Preventive mastectomy (BRCA1/2 malignant mutation with obvious family history of breast cancer and other high-risk groups);
  6. Preoperative clinical manifestations and imaging data showed no distant metastasis;
  7. No history of breast cancer or other serious underlying diseases in the past;
  8. performance status score ≥ 70;
  9. score ≤ 2 ;
  10. The surgical procedure includes endoscopic-assisted/conventional mastectomy, sentinel lymph node biopsy/axillary lymph node dissection and immediate breast reconstruction;
  11. Participants are able to understand the research process, voluntarily join the study, sign forms, have good compliance, and cooperate with follow-up;
  12. No swallowing difficulties; No shoulder joint movement disorders;
  13. Complete clinical data.

Exclusion criteria

Exclusion Criteria:

  1. Male breast cancer or inflammatory breast cancer;
  2. breast cancer (stage IV); Tumor invasion of the skin, pectoralis major muscle, or NAC;
  3. The clinical data is basically incomplete;
  4. Previously received chemotherapy in an external hospital or has undergone tumor resection in an external hospital;
  5. Bilateral breast cancer surgery;
  6. Other surgical methods;
  7. Preoperative distant metastasis or supraclavicular lymph node dissection;
  8. Complicated with other malignant tumors or had malignant tumors other than breast cancer in recent 5 years;
  9. The serious disease of non malignant tumors combined will affect the patient's compliance or put the patient in a dangerous state;
  10. Dementia, intellectual disability, or any mental illness that hinders understanding of forms.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
800 participants (estimated)

Study arms

  • Experimental
    endoscopic-assisted mastectomy and immediate breast reconstruction

    endoscopic-assisted mastectomy and immediate breast reconstruction

    Procedure: endoscopic-assisted mastectomy and immediate breast reconstruction

  • Experimental
    mastectomy and immediate breast reconstruction

    mastectomy and immediate breast reconstruction

    Procedure: mastectomy and immediate breast reconstruction

Interventions

  • Procedureendoscopic-assisted mastectomy and immediate breast reconstruction

    endoscopic-assisted mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer

  • Proceduremastectomy and immediate breast reconstruction

    conventional mastectomy and sentinel lymph node biopsy/axillary lymph node dissection in the management of breast cancer

06

What researchers measure

Primary outcomes

  1. Local recurrence free survival rate (LRFS)

    Local recurrence refers to the recurrence of the chest wall or breast on the same side as the surgical site.

    Time frame: 3 years

  2. Regional recurrence free survival rate (RRFS)

    Regional recurrence refers to the recurrence in the drainage area of ipsilateral internal mammary lymph nodes, axillary lymph nodes, or supraclavicular and infraclavicular lymph nodes.

    Time frame: 3 years

Secondary outcomes

  1. Disease free survival (DFS)

    The time from entry into the study to the first tumor recurrence or metastasis, or death of the subject for any reason.

    Time frame: 3 years

  2. Distant metastasis free survival rate (DMFS)

    Distant transfer refers to the transfer to any other location.

    Time frame: 3 years

  3. Main complication rate

    The Clavien-Dindo classification of surgical complications, including long term outcomes and short term outcomes.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Dec 2027, 35 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2025
First posted
Feb 10, 2025
StartActual
Jan 1, 2025
Primary completionEst.
Dec 31, 2027
CompletionEst.
Dec 31, 2028
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06817954
Responsible party
Sponsor
First posted
Feb 10, 2025
Start date
Jan 1, 2025
Primary completion
Dec 31, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
May 1, 2026

Study contacts

Qiang Ding, Professor
Contact
dingqiang@njmu.edu.cn
13951731373

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion